Is Sermorelin Legal in California?

The Short Answer: Sermorelin Is Legal in California With a Prescription

Sermorelin is not a controlled substance under the Controlled Substances Act, and California has no state law that independently restricts its prescribing or dispensing beyond ordinary legend-drug rules. A California-licensed physician can legally prescribe it; a properly licensed compounding pharmacy can legally prepare and dispense it. The catch is that no commercially manufactured sermorelin product holds current FDA approval in the United States, so the only lawful supply chain runs through licensed compounding.

Why There Is No Off-the-Shelf Commercial Product

Serono's brand-name product Geref (sermorelin acetate for injection) received FDA approval in 1997 for the diagnosis of GH deficiency in children. Serono voluntarily withdrew Geref from the U.S. Market in 2008 for business reasons unrelated to safety. The FDA did not revoke the approval for cause, and the agency has never placed sermorelin on any list of banned or withdrawn-for-safety substances. That distinction matters: a voluntary marketing withdrawal is legally different from a safety-based revocation. Compounders may prepare drugs whose brand versions were voluntarily withdrawn, as long as compounding rules are followed.

What "No Current Approval" Means for Patients

Without a commercially approved product, patients cannot walk into a retail pharmacy and fill a sermorelin prescription from shelf stock. Every legal supply of sermorelin in California flows through a compounding pharmacy, either a 503A patient-specific compounder or a 503B outsourcing facility. That is not a regulatory gray area. It is a well-established compounding pathway used for hundreds of other drugs whose manufacturers discontinued commercial production.

Federal Framework: FDA, Compounding Law, and the Bulks List

Understanding sermorelin's legal status starts at the federal level, because federal law sets the floor that California must meet or exceed.

The Federal Food, Drug, and Cosmetic Act and Compounding

Sections 503A and 503B of the FD&C Act govern pharmacy compounding. Under 21 U.S.C. 353a, a licensed pharmacist at a 503A pharmacy may compound a drug product for an identified individual patient based on a valid prescription, provided the pharmacy does not compound "essentially a copy" of a commercially available drug and does not use a bulk substance that appears on the FDA's "negative list" (Category 1 bulks). Under 21 U.S.C. 353b, a 503B outsourcing facility may compound larger batches without patient-specific prescriptions but must use only bulk substances that the FDA has affirmatively placed on the Category 1 approved list.

Sermorelin's Position on the FDA Bulks Lists

The FDA maintains two lists for 503B bulk substances: a Category 1 "nominated and under review or approved" list and a Category 2 "not appropriate for compounding" list. As of this article's review date, sermorelin does not appear on the affirmatively approved 503B Category 1 list, which means a 503B outsourcing facility operating strictly by the book should not be compounding sermorelin in large batches for office use without a patient-specific prescription. Sermorelin also does not appear on the Category 2 negative list, meaning it is not expressly prohibited.

The practical implication: 503A patient-specific compounding of sermorelin remains available because the drug is not on any negative or prohibited list and is not a copy of a currently marketed product. Patients and prescribers should confirm current list status directly with the FDA or a regulatory attorney before proceeding, because the FDA updates these lists periodically. The current 503B bulks list is maintained at fda.gov.

The "Essentially a Copy" Rule

The FD&C Act prohibits 503A pharmacies from compounding a drug that is "essentially a copy" of a commercially available product. Because no sermorelin product is currently on the U.S. Market, this prohibition does not apply. The FDA's guidance on essentially-a-copy determinations is published at fda.gov.

California State Framework: What State Law Adds

California does not impose a separate scheduling tier on sermorelin above and beyond federal rules. The relevant state-level requirements come from three sources: the California Business and Professions Code, the California Health and Safety Code, and regulations from the California State Board of Pharmacy.

California Business and Professions Code and Off-Label Prescribing

California Business and Professions Code Section 2234 defines unprofessional conduct but does not prohibit off-label prescribing. Physicians routinely prescribe drugs for indications not listed in FDA-approved labeling, and this practice is legal in California as it is in every other U.S. State. A physician prescribing compounded sermorelin for adult growth hormone deficiency, age-related GH decline, or other conditions is engaged in lawful off-label prescribing, provided the decision is medically justified and documented in the patient record.

California State Board of Pharmacy Compounding Rules

The California State Board of Pharmacy licenses and inspects compounding pharmacies under California Code of Regulations Title 16, Section 1735 et seq. A pharmacy compounding sermorelin for California patients must hold an active California compounding pharmacy license. If the pharmacy is located out of state and ships to California patients, it must hold a nonresident pharmacy permit from the California Board of Pharmacy in addition to its home-state license. The California Board of Pharmacy's compounding regulations align with, and in some respects exceed, USP Chapter 797 sterile compounding standards because sermorelin is supplied as a sterile injectable. Details are at the California State Board of Pharmacy website.

Telehealth Prescribing in California

California Assembly Bill 2395 (2022) and the state's telehealth statute (Business and Professions Code Section 2290.5) allow physicians to establish a valid patient-physician relationship and issue prescriptions via synchronous audio-video telehealth. A physician does not need to examine a patient in person before prescribing compounded sermorelin as long as the telehealth encounter meets the standard of care, the physician is licensed in California, and appropriate laboratory testing (at minimum, IGF-1 and a metabolic panel) has been reviewed. This framework is what enables California-based telehealth platforms, including HealthRX, to offer legal sermorelin prescriptions to California residents.

How to Get Sermorelin Legally in California

The path to a legal sermorelin prescription in California involves four steps, each tied to a specific regulatory requirement.

Step 1: Consult a California-Licensed Physician

Only a physician (MD or DO) licensed by the Medical Board of California, or a nurse practitioner or physician assistant with prescriptive authority, can issue a valid prescription. The consultation must include a clinical evaluation sufficient to support the prescribing decision. That evaluation typically includes a review of symptoms consistent with GH deficiency or GH decline, a medical history, and laboratory workup.

Step 2: Complete the Required Laboratory Workup

Standard clinical practice calls for baseline insulin-like growth factor 1 (IGF-1) measurement before starting sermorelin. IGF-1 is the primary surrogate marker for GH secretion and is the standard endpoint used in growth hormone research, including the key trials that informed Geref's original FDA approval. Additional labs commonly ordered include a comprehensive metabolic panel, fasting lipids, and thyroid function. The Endocrine Society's clinical practice guideline on adult GH deficiency recommends IGF-1 as the primary monitoring marker and notes that GH stimulation testing may be appropriate for formal diagnosis.

Step 3: Receive a Patient-Specific Prescription

The prescriber issues a written or electronic prescription specifying the patient's name, the compound (sermorelin acetate), the concentration (commonly 5 mg/mL or 9 mg/mL in bacteriostatic water), the volume per dose, frequency, and quantity. This patient-specific prescription is the legal basis for a 503A pharmacy to compound the product.

Step 4: Pharmacy Dispensing and Shipment

The prescription is sent to a California-licensed or California-permitted compounding pharmacy. The pharmacy compounds the sermorelin under USP 797 sterile conditions, seals it in a labeled vial, and dispenses or ships it directly to the patient. Federal law allows licensed pharmacies to ship controlled and non-controlled substances interstate, and sermorelin, being non-controlled, faces no DEA shipping restrictions.

Clinical Background: What Sermorelin Does and Why Physicians Prescribe It

Sermorelin is a 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH). It binds GHRH receptors on pituitary somatotrophs and stimulates the pulsatile secretion of endogenous GH, rather than delivering exogenous GH directly. This mechanism preserves the feedback loop that prevents GH excess, which is one reason clinicians consider it a lower-risk alternative to recombinant human GH (rhGH) for patients who do not meet the narrow FDA criteria for rhGH therapy.

Evidence Base for Adult Use

The evidence base for sermorelin in adults is smaller than for rhGH, but not negligible. A double-blind, placebo-controlled trial published in the Journal of Clinical Endocrinology and Metabolism (Corpas et al., 1992; N=17) demonstrated that six months of nightly sermorelin at 0.5 mg subcutaneous increased mean serum IGF-1 concentrations significantly compared to placebo (P<0.01) and improved sleep quality and body composition markers. While this trial is modest in size, it established the pharmacodynamic proof of concept that sermorelin reliably stimulates the GH/IGF-1 axis in older adults. The study is indexed at PubMed.

A later randomized controlled trial by Walker et al. (1990) in the Journal of Pediatrics (the key pediatric data supporting Geref) confirmed the efficacy of sermorelin in stimulating GH secretion, with a response rate exceeding 70% at the 1 mcg/kg dose. That trial is indexed at PubMed.

Prescribers cite this literature when making a clinical case for off-label adult use, along with the Endocrine Society's position that age-related GH decline is physiologically measurable and that therapeutic intervention may be appropriate in carefully selected patients.

Common Indications Seen in California Telehealth Practice

California physicians prescribing sermorelin most often document one or more of the following clinical indications:

• Adult-onset or age-related growth hormone deficiency (low IGF-1 with symptoms)
• Poor sleep quality with associated GH secretory impairment
• Reduced lean body mass with elevated body fat percentage despite resistance training
• Recovery from catabolic illness or injury where GH axis support is clinically appropriate

None of these indications carry an FDA-approved label for sermorelin because Geref's approved indication was pediatric GH deficiency diagnosis. Off-label use in adults is legal, common, and consistent with the standard of care when properly documented.

Dosing and Monitoring in Clinical Practice

Typical dosing is 0.2 to 0.3 mcg/kg subcutaneous injection administered at bedtime, timed to coincide with the natural nocturnal GH pulse. At 80 kg body weight, that translates to 160 to 240 mcg per injection. Some protocols use flat dosing of 200 to 300 mcg nightly. IGF-1 is rechecked at 12 weeks to assess response; a target range of 200 to 300 ng/mL (age-adjusted) is commonly used in clinical practice. If IGF-1 does not rise adequately after 12 to 16 weeks, the prescriber may evaluate for pituitary insufficiency or a different peptide protocol.

The HealthRX clinical team uses a standardized four-point decision framework for sermorelin candidacy: (1) baseline IGF-1 below the age-adjusted 25th percentile, (2) at least two functional symptoms from a validated GH deficiency symptom checklist, (3) absence of active malignancy or pituitary adenoma on imaging, and (4) documented trial of sleep hygiene and lifestyle optimization with inadequate response. Candidates meeting all four criteria are considered appropriate for a 12-week sermorelin trial with repeat IGF-1 at week 12.

Risk Areas: Where Legal Trouble Actually Arises

Most legal risk around sermorelin in California does not come from state-level restrictions that don't exist. It comes from deviations at the federal compounding level or from unlicensed prescribing.

Purchasing Sermorelin Without a Prescription

Some websites sell sermorelin labeled "for research use only" (RUO). Purchasing or possessing RUO sermorelin for personal administration is legally problematic. The FDA's position, stated in its 2019 guidance document on research-use-only products, is that selling a peptide as RUO while knowing it will be used for human therapeutic purposes violates the FD&C Act. More practically, RUO products are not compounded under USP 797 conditions and have no sterility or potency guarantee. Patients who purchase from these sources take on both legal and medical risk. The FDA's warning letter history on peptide sellers is searchable at fda.gov.

Using a Non-Licensed or Out-of-State Non-Permitted Pharmacy

If a telehealth platform ships sermorelin to a California patient from a pharmacy that does not hold a California nonresident pharmacy permit, both the pharmacy and potentially the prescribing platform may be in violation of California law. Patients have the right to ask any prescriber or platform: "What is the name and California pharmacy permit number of the dispensing pharmacy?" A legitimate operation will answer this question immediately.

Prescribers Without California Licensure

A physician licensed only in another state cannot legally prescribe to a California patient under standard rules, even via telehealth, unless that physician also holds a California license or a valid California telemedicine license. The Medical Board of California enforces this rule actively. Any platform directing California patients to out-of-state-only prescribers is operating outside California law.

Sermorelin vs. Other GHRH Analogues: Legal Distinctions Matter

Sermorelin is sometimes grouped with other growth hormone secretagogues including ipamorelin, CJC-1295, tesamorelin, and GHRP-2. Their legal statuses differ in important ways.

Tesamorelin (Egrifta) holds current FDA approval for HIV-associated lipodystrophy, making it a commercially available product. Compounding tesamorelin for non-approved indications runs into the "essentially a copy" prohibition more directly than sermorelin does. The FDA has sent warning letters to compounders preparing tesamorelin.

Ipamorelin and CJC-1295 are GHRP and GHRH analogues, respectively, that have never held FDA approval and appear on the FDA's list of bulk substances that may not be used in 503A compounding (the negative list published at fda.gov). Their compounding status is materially more restricted than sermorelin's. Patients and physicians should not assume that all GHRH-class peptides share the same regulatory treatment.

Sermorelin's cleaner status, relative to ipamorelin and CJC-1295, is one practical reason clinicians and patients in California prefer it as a legally straightforward starting point for GH-axis support.

What California Patients Should Confirm Before Starting

Before beginning a sermorelin protocol, a California patient should verify each of the following:

• The prescribing physician holds an active California medical license (verifiable at the Medical Board of California license lookup).
• The dispensing pharmacy holds an active California State Board of Pharmacy license or nonresident pharmacy permit (verifiable at pharmacy.ca.gov).
• The prescription is individualized, not a standing order for a patient population.
• Baseline IGF-1 and a metabolic panel were reviewed before the prescription was issued.
• The product label states it was compounded in a licensed pharmacy under sterile USP 797 conditions.

Meeting these five checkpoints does not guarantee a clinical outcome, but it does confirm that the prescription is legally sound under both California and federal law.